US 12,128,045 B2
Platinum-resistant cancer treatment
Udai Banerji, Sutton (GB)
Assigned to BTG International Limited, London (GB)
Filed by BTG International Limited, London (GB)
Filed on May 3, 2021, as Appl. No. 17/306,052.
Application 17/306,052 is a continuation of application No. 16/810,160, filed on Mar. 5, 2020, granted, now 11,026,948.
Application 16/810,160 is a continuation of application No. 16/613,912, abandoned, previously published as PCT/IB2018/053428, filed on May 16, 2018.
Claims priority of provisional application 62/513,627, filed on Jun. 1, 2017.
Claims priority of application No. 1707864 (GB), filed on May 16, 2017.
Prior Publication US 2021/0252001 A1, Aug. 19, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/517 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/4745 (2006.01); A61K 31/502 (2006.01); A61K 31/519 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/7068 (2006.01); A61K 33/243 (2019.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01); A61P 35/00 (2006.01)
CPC A61K 31/517 (2013.01) [A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/4745 (2013.01); A61K 31/502 (2013.01); A61K 31/519 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); A61K 47/643 (2017.08); A61K 47/6929 (2017.08); A61P 35/00 (2018.01); A61K 2039/545 (2013.01)] 25 Claims
 
1. A method of treating cancer in a patient in need thereof comprising administering to the patient a compound of formula I

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or ester thereof, wherein:
the cancer has the characteristic of being a type prone to being or becoming refractory or resistant to platinum drug based therapy,
the compound or pharmaceutically acceptable salt or ester thereof is administered to the patient at a dose of from 6 mg/m2 to 14 mg/m2 of compound or pharmaceutically acceptable salt or ester thereof per patient body surface area per administration, and
each of the administrations is in a 28-day cycle at 14-day intervals.